Sirolimus as a new drug to treat RIF patients with elevated Th17/Treg ratio: A double-blind, phase II randomized clinical trial.
Ahmadi M, Abdolmohamadi-Vahid S, Ghaebi M, Dolati S, Abbaspour-Aghdam S, Danaii S, Berjis K, Madadi-Javid R, Nouri Z, Siahmansouri H, Babaloo Z, Nouri M, Yousefi M.
Ahmadi M, et al. Among authors: nouri m, nouri z.
Int Immunopharmacol. 2019 Sep;74:105730. doi: 10.1016/j.intimp.2019.105730. Epub 2019 Jul 9.
Int Immunopharmacol. 2019.
PMID: 31299610
Clinical Trial.